Nurix Therapeutics, Inc. (NRIX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$25.71

From 52W high−8.46%

Volume2.72M

Market cap$2.64B

P/E (TTM)—

P/S (TTM)71.8x

Div yield—

Key dataSep 18, 2026

Open

$25.71

From 52W high

−8.46%

Volume

2.72M

Market cap

$2.64B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.1x

P/E (TTM)

—

RSI (14)

45.5

MomentumView details →

1D Return

−0.24%

YTD Return

+32.10%

SummaryUpdated May 1, 2026

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a biopharmaceutical company founded in 2009 and headquartered in San Francisco, California. The company went public in July 2020, raising capital to advance its innovative approach to drug discovery and development. Nurix focuses on developing small molecule therapies that leverage targeted protein degradation, a cutting-edge approach in biotechnology that aims to treat cancer and immune disorders by selectively destroying disease-causing proteins within cells.

Ask drillr about Nurix Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−7.1x

EV/Sales

61.3x

P/S (TTM)

71.8x

P/B (TTM)

6.6x

ProfitabilityView details →

Gross Margin

−165.51%

Net Margin

−928.44%

EBITDA Margin

−869.64%

ROE (TTM)

−84.78%

ROA (TTM)

−63.74%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

−58.40%

EPS YoY

−32.18%

FCF YoY

−34.87%

Revenue CAGR 3Y

+29.55%

EPS CAGR 3Y

−5.90%

EBITDA YoY

−52.19%

MomentumView details →

1D Return

−0.24%

YTD Return

+32.10%

1Y Return

+196.92%

RSI (14)

45.5

vs 50D SMA

−0.34%

vs 200D SMA

+29.66%

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

6.34x

Quick Ratio

6.34x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.81

EPS Surprise

−10.96%

Beats (12Q)

5/12

Next Q EPS Est

−$0.09

Avg Surprise (4Q)

−8.79%

Rev Surprise

−40.85%

Financials snapshotView financials →

Revenue (TTM)

36.77M

Net Income (TTM)

−341.35M

Op. CF (TTM)

−293.70M

Next earningsOct 8, 2026 →

Latest newsMore news →

Nurix Therapeutics appointed Wes Burwell as its Chief Human Resources Officer on August 20, 2026.31d ago

Nurix Therapeutics' stock reached a new 52-week high of $26.04 on Tuesday after Royal Bank of Canada raised its price target.40d ago

Similar companies

Braveheart Bio, Inc.BRVE Clover Biopharmaceuticals, Ltd.02197.HK Disc Medicine, Inc.IRON NewAmsterdam Pharma Company N.V.NAMS Beam Therapeutics Inc.BEAM Immunome, Inc.IMNM Find similar companies →

Latest newsMore news →

Nurix Therapeutics appointed Wes Burwell as its Chief Human Resources Officer on August 20, 2026.31d ago Nurix Therapeutics' stock reached a new 52-week high of $26.04 on Tuesday after Royal Bank of Canada raised its price target.40d ago